Interim report
Page 1
Viyash Viyash Scientific Limited ( Formerly known as Sequent Scientific Limited ) Registered Office : 3rd Floor , Srivalli's Corporate , Plot No.290 , Road No.6 , Sy.No.33 , 34P to 39 , Guttala Begumpet , Jubilee Hills , Hyderabad , Shaikpet , Telangana , India - 500033 T : +91 40 23635000 , E : investorrelations@viyash.com Website : www.viyash.com CIN : L99999TS1985PLC196357 August 11 , 2026 To , BSE Limited Phiroze Jeejeebhoy Towers , Dalal Street , Fort , Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza , Bandra - Kurla Complex , Bandra ( East ) , Mumbai 400 051 - Symbol : VIYASH Scrip code : 512529 Dear Sir / Madam , Subject : Outcome of Board Meeting held on August 11 , 2026 We refer to our intimation dated August 03 , 2026 , regarding the meeting of the Board of Directors ( " Board " ) of the Company scheduled to be held on Tuesday , August 11 , 2026 . In this regard , we would like to inform you that the Board at its Meeting held today i.e. , on Tuesday , August 11 , 2026 , inter - alia , considered and approved the following : 1. Unaudited Standalone and Consolidated Financial Results along with Independent Auditor's Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30 , 2026 . Pursuant to the Regulation 33 ( 3 ) of SEBI ( Listing Obligations and Disclosure Requirements Regulations ) , 2015 ( “ SEBI Listing Regulations " ) read with applicable SEBI circular ( s ) , the Unaudited Financial Results ( Standalone and Consolidated ) along with Limited Review Report issued by the Statutory Auditors of the Company , for the quarter ended June 30 , 2026 , are enclosed herewith as " Annexure A " . 2. Allotment of equity shares to the employees of the Company and its Subsidiaries under the Viyash Scientific Limited Employee Stock Option Scheme , 2026 ( “ ESOP Scheme 2026 " ) . Allotment of 10,30,775 Equity Shares of Rs . 2 / - each , fully paid to eligible optionees at an exercise price of Rs . 101 / - per equity share ( including premium of Rs . 99 / - per equity share ) on exercise of the options granted under Viyash Scientific Limited Employee Stock Option Scheme , 2026 ( " ESOP Scheme 2026 " ) . The said Equity shares shall rank pari passu in all respects with the existing equity shares of the Company . Consequent to the proposed allotment of the aforesaid equity shares , the issued and the paid - up equity share capital of the Company will increase from Rs . 87,77,53,626 / - consisting of 43,88,76,813 Equity Shares of Rs . 2 each to Rs . 87,98,15,176 / - consisting of 43,99,07,588 Equity Shares of Rs . 2 each .
Page 2
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 3. Incorporation of a wholly owned subsidiary in Vietnam and investment therein. Approved the incorporation of a step-down subsidiary in Vietnam through the Company’s subsidiary Alivira Animal Health Limited, India (“AAHL”) or its step-down subsidiary Alivira Animal Health Limited, Ireland (“AAHL Ireland”). The necessary details required in terms of Regulation 30 read with Sc hedule III Part A , Para A (1) of the SEBI Listing Regulations read with applicable SEBI circular(s) as amended from time to time is enclosed as “Annexure – B”. 4. Subscription of equity shares in Alivira Animal Health Limited (“AAHL”) , a wholly owned subsidiary, through Rights Issue. Approved subscription to equity shares of AAHL on rights basis (“ Rights Issue”), a wholly owned subsidiary of the Company, for an overall consideration of up to Rs. 400,02,15,648 (Rupees Four Hundred Crore Two Lakh Fifteen Thousand Six Hundred and Forty-Eight Only). The subscription amount payable towards the proposed Rights Issue shall be adjusted against the intercompany loan extended by the Company from time to time, and confirmation in respect of the said adjustment shall be obtained. The proposed conversion is intended to strengthen AAHL’s capital structure and reduce interest burden. Being a wholly owned subsidiary, there is no change in the shareholding percentage of the Company in AAHL, pursuant to this investment. The necessary details required in terms of Regulation 30 read with Schedule III , Part A, Para A (1) of the SEBI Listing Regulations read with applicable SEBI circulars as amended from time to time is enclosed as “Annexure – C”. The Board Meeting commenced at 11:30 a.m. and concluded at 12:46 p.m. We request you to kindly take the above on record. Thank you, Yours faithfully, For Viyash Scientific Limited Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer Encl: as above
Page 3
SR BC & CO LLP 12th Floor, The Ruby 29 Senapati Bapat Marg Dadar ( West) Chartered Accountants Mumbai - 400 02B, India Tel : +9122 6B198000 Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Viyash Scientific Limited (formerly known as Sequent Scientific Limited) 1. We have reviewed the accompanying statement of unaudited standalone financial results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Company") which includes Sequent Scientific Employee Stock Option Plan Trust (the "Trust") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly , we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended , read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to Note 3 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the Transferor Companies have been amalgamated with the Company . The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations, applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter ended 30 June 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation, as described further in the said note. Our conclusion is not modified in respect of this matter. SR BC & co LLP, a Limited Liablhty Partne~hip with LLP Identity No. AAB-4318 Reqd. Office: 22, Camac Street, Block 'B', 3rd Floor, Kolkala-700 016
Page 4
SR BC& CO LLP Chartered Accountants Viyash Scientific Limited (formerly known as Sequent Scientific Limited) Page 2 of 2 6. The accompanying Statement includes unaudited interim financial results and other financial information in respect of Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total revenues of Rs. Nil, total net loss after tax of Rs. 0.01 million and total comprehensive expense of Rs. 0.01 million for the quarter ended June 30, 2026. These unaudited interim financial results and other unaudited financial information of the Trust have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Trust is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results and other unaudited financial information of the Trust are not material to the Company. Our conclusion on the Statement in respect of matter stated in paragraph 6 above is not modified with respect to our reliance on the financial results certified by the Management. For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003 per Anil Jobanputra Partner Membership No.: 110759 UDIN: 26110759TORHIA6435 Place: Mumbai Date: August 11 , 2026
Page 5
Viyash Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Regd. Office: 3rd Floor , Srrvalli's Corporate , Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills , Sha1kpet, Hyderabad-500033 , Telangana , India. E-mail : 1nvestorrela t1ons@v1yash.in, E-ma,1: ,nfo@viyash.com , Website : www.viyash.com Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Sr. No. I II Ill IV V Revenue from operations Other income Total income (1+11) Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade Particulars (c) Chanqes in inventories of finished qoods, work-in-proqress and stock-in-trade (d) Employee benefits expenses (refer note 5) (e) Finance costs (f) Depreciation and amortisation expenses (q) Other expenses Total expenses (IV) Profit before tax and exceptional items (Ill-IV) VI Exceptional items (refer note 4) VII Profit before tax (V-VI) VIII Tax expense I (credit) (a) Current tax (b) D@fwrrwd t.x Total tax expense I (credit) (VIII) IX Profit after tax (VII-VIII) X Other comprehensive income I (loss) Items that will not be reclassified to profit or loss (a) Re-measurement loss on defined benefits plans (b) Fair value qain / (loss) from investment in equity instruments (c) Income tax relating to items that will not be reclassified to profit or loss Total other comprehensive income I (loss) (net of tax) XI Total comprehensive income I (loss), net of tax (IX+X) XII Equity share capital (face value of~ 2 each) (refer note 3) XIII Other equity XIV Earnings per equity share: (face value of, 2 each) (not annualised) (1) Basic in ~ (refer note 6) (2) Diluted in ~ (refer note 6) See accompanying notes to unaudited standalone financial results 3 months ended 30-June-2026 Unaudited 3,536.90 145.90 3,682.80 1,653.10 34.20 (55.00) 706.40 14.40 324.10 726.70 3,403.90 278.90 278.90 46.20 2J.S0 69.70 209.20 (3.70) 0.10 0.90 (2.70) 206.50 873.70 0.48 0.47 Preceding 3 months ended 31-March-2026 Audited {refer note 7} 3,724.90 197.50 3,922.40 1,561.60 182.10 (40.40) 574.50 25.30 311 .60 820.20 3,434.90 487.50 487.50 149.80 (20.40) 129.40 358.10 (10.60) (0.30) 2.90 (8.00) 350.10 873.70 0.82 0.81 Corresponding 3 months ended in previous period 30-June-2025 Unaudited (Restated) {refer note 3} 3.281 .80 129.00 3,410.80 1,326.40 2.20 153.60 538.10 60.20 308.90 767.00 3,156.40 254.40 (12.50) 241.90 112.10 (4J.20) 68.90 173.00 0.10 0.10 173.10 500.70 0.40 0.40 (fin million) Previous year ended 31-March-2026 Audited 13,820.60 662.60 14,483.20 5,998.20 284.10 (43.60) 2,137.50 162.10 1,241.50 3,099.10 12,878.90 1,604.30 (442.10) 1,162.20 152.10 2G1.40 403.50 758.70 (13.00) (0.20) 3.40 (9.80) 748.90 873.70 31 ,017.00 1.75 1.72
Page 6
Notes: Viyash Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Regd Office 3rd Floor Snvalli's Corporate Plot No. 290 Road No. 6, SYN 33 34P TO 39 Guttala Begumpet. Jubilee Hills, Sha1kpet, Hyderabad-500033 , Telangana. India E-mail· 1nvestorrelat10ns@viyash.1n. E-maj · info@vtyash.com Website· www.vtyash.com Tel No .· +91 40 23635000 CIN: L99999TS1985PLC196357 The above statement of unaudited standalone financial results of Viyash Scientific Limited has been prepared ,n accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 11 August 2026. The Statutory Auditors have earned out a limited review of lhe unaudited standalone financial results and issued unmodified reports thereon. The Company is primarily engaged In the business of 'Pharmaceutica ls' There Is no separate reportable segment as per Ind AS 108- Operating Segments The Board of Directors of the Company al their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgama tion (the Scheme) amongst the Company , Sequent Research Limited (wholl y owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Lile Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferor Companies' ) in terms of Section 230-232 and other applicable provisions of Companies Act, 2013 The Hon'ble National Company Law Tribunal (NCLT) , Hyderabad vide ,ts order dated 18 November 2025 sanctioned the Scheme with an Appointed dale of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad .As per the terms of the Scheme , the Company has alloted 18 19,21,827 fully paid-up equity shares of face value oft 2 each, as per the share exchange ratio of 56 fully paid up equity shares of face value off 2 each of the Company for every 100 fully paid-up equity shares of face value of f 10 each l1eld by eligible shareho lders of erstwhie Viyash Life Sciences Private Limited as on the record date. The Company has also alloted 2,03.41.257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a conside ration ol f 925.20 million during the previous year ended 31 March 2026 (representing 25% on Warran t consideration as per the Scheme) The Company has accounted for the business combina tion transaction using the 'Pooling of interest method' as given under Append ix C to Ind AS 103, 'Business Combinations of Entitles under Common Control', In acco rdance with the accoun ting treatment prescribed In lhe Scheme. Accordingly, the financial results of the company in respect of the correspo nding prior periods have been restated as if the aforesaid business combina tion had occurred from the beginning of the preceding period (i.e. 01 April 2024) as per below a) Details of revenue and profit restated due to the Scheme of Amalgamation· (fin Million) Revenue from operations Profit before tax Profil afler tax Total comprehensive income (net of tax) Particulars Basic earnings per equity share (inf) (not annualised) Diluted earnings per equity share (1n ~) (not annualised) Exceptional items include · P;artioulan;; Expenses related to the Scheme of Amalgama tion Total (a) The Company has recorded below transaction costs pertaining lo Scheme : 3 month s ended 30-June-2026 ~Joto rafaranaa Unaudited (a) Corresponding 3 months ended in previous period 30-June-2025 Reoorted Restated 410.70 3,281 .80 47.80 241.90 33.70 173.00 33.70 173.10 0.14 0.40 0.13 0.40 Preceding Corresponding 3 months ended in 3 months ended previous period 31-March-2026 1.n. hmo.?O?'i Audited Unaudited {rofor nnto 7) (Restated) (refer note 3} 12.50 12.50 (i) Stamp duty recognized on an estimated basis amou nting lo~ 296.50 million for the previous year ended 31 March 2026 payable pursuant lo scheme. (fin Million) Previous year ended 31-March-2026 Audited 442. 10 442 .10 (ii) Transactio ns costs with respect to fees payable lo merchant banker In relation lo Scheme amou nting to~ 10.10 million for quarter ended 30 June 2025 and f 107.60 million for the previous year ended 31 March 2026. (iii) Other transaction costs with respect lo fees payable to lawyers and other consultants engaged in relation to the Scheme amount ing to~ 2.40 million for quarter ended 30 June 2025 and ~38 million for the year previous ended 31 March 2026. Pursuant to the Composite Scheme of Amalgamation (refer note 3 above), the Board of Directors and Nomination and Remuneration Committee (NRC) at its meeting held on February 05, 2026 approved the adoption of Viyash Scientific Limited - Employee Stock Option Scheme 2026 ("ESOP Scheme 2026"), subject to receipt of necessary approvals. During the quarter ended 30 June 2026, on receipt of necessary approvals, Compa ny has granted 13,098,000 employee stock options, representing 2.8% of the post-amalgama tion paid-up share capital of the Company unde r ESOP Scheme 2026. This has resulted in an incremen lal expense of - INR 191 million for the quarter ended 30 June 2026, which has been recognize d under "Employee benefit expense" in the financial results. Weighted average number of shares considered for calculation of basic and diluled earnings per share for all the perk>ds reported includes the weighted average effect of equity shares and warrants alloted pursuant to the Scheme as described in note 3 above and outstanding share optk>ns under employees share option plan. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year lo date figures uplo the third quarter of the relevant financial year. Hyderabad, 11 August 2026
Page 7
SR 8 C & CO LLP Chartered Accountants 12th Floor, The Ruby 29 Senapati Bapat Marg Dadar ( West) Mumbai - 400 028, India Tel : +91 22 6819 8000 Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Viyash Scientific Limited (formerly known as Sequent Scientific Limited) 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Holding Company") including Sequent Scientific Employee Stock Option Plan Trust (the "Trust") and its subsidiaries (the Holding Company, the Trust and its subsidiaries together referred to as the "Group"), for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") . 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations , to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure 1 to the auditor's review report. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement , prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended , read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We draw attention to Note 3 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the Transferor Companies have been amalgamated with the Company The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations , applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter ended 30 June 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation., as described CO further in the said note. Our conclusion is not modified in respect of this matter. c, ~ l(.~ ~ ... (I) Q:' Cl) ... q, SR BC & co LLP. a Limited Liability Partnership with LLP loenlily No. AAB-4318 Reo<I. Office: 22. Camac Street. Block 'B'. 3rd Floor, Kolkala-700 016
Page 8
SR BC& CO LLP Chartered Accountants Viyash Scientific Limited (formerly known as Sequent Scientific Limited) Page 2 of 3 7. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of: • Thirteen subsidiaries, whose unaudited interim financial results include total revenues of Rs. 4,157.20 million, total net profit after tax of Rs. 394.90 million and total comprehensive income of Rs. 394.90 million for the quarter ended June 30, 2026 as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries, is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us. 8. The accompanying Statement includes unaudited interim financial results and other financial information in respect of: • Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total revenues of Rs. Nil, total net loss after tax of Rs. 0.01 million and total comprehensive expense of Rs. 0.01 million for the quarter ended June 30, 2026 and • Two subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 42. 70 million, total net loss after tax of Rs. 8.40 million and total comprehensive expense of Rs. 8.40 million for the quarter ended June 30, 2026. The unaudited interim financial results and other unaudited financial information of the Trust and these subsidiaries have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement in respect of matters stated in paragraph 7 and 8 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management. For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003 ~ Partner Membership No.: 110759 UDIN: 26110759VDYZPN6078 Place: Mumbai Date: August 11, 2026
Page 9
SR BC & CO LLP Chartered Accountants Viyash Scientific Limited (formerly known as Sequent Scientific Limited) Page 3 of 3 Annexure 1 to Auditor's report Name of the Holding Company 1. Viyash Scientific Limited Including its following subsidiaries: 2. Alivira Animal Health Limited, India 3. Appco Pharma LLC Including its following subsidiary: 4. Alivira Animal Health Limited, Ireland Including its following subsidiaries and sub subsidiaries: 5. Vila Viria Participacions, S. L. 6. Laboratories Karizoo, S.A. 7. Phytotherapic Solutions S. L. 8. Alivira Saude Animal Ltda 9. Alivira Saude Animal Brasil Participacoes Ltda 10. Expeden Distribuidora De Produtos Veterinaries Ltda 11. Provet Veteriner Urunleri San. Ve Tic. A. $. 12. Topkim Topkapi lla9 premiks Sanayi Ve Ticaret A.$ . 13. Laboratorios Karizoo, S.A. de C.V. (Mexico) 14. Alivira Animal Health UK Limited 15. Alivira Italia S. R. L. 16. Alivira Animal Health USA LLC 17. Alivira BV 18. N-Vet AB 19. Bremer Pharma GmbH 20. Alivira NV Including following Trust: Sequent Scientific Employee Stock Option Plan Trust
Page 10
Viylsh Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Sha1kpet, Hyderabad-500033 , Telangana, India. E-mail: investorrelations@viyash.com , E-mail: 1nfo@viyash.com, Website : www.viyash.com Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Sr. No Particulars I Revenue from operations II Other income Ill Total income (1+11) IV Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (refer note 5) (e) Finance costs (f) Depreciation and amortisation expenses (g) Other expenses (h) Net monetary (gain)/ loss on hyperinflation economy (refer note 6) Total expenses (IV) V Profit before tax and exceptional items (Ill-IV) VI Exceptional items (refer note 4) VII Profit before tax (V-Vl) VIII Tax expense I (credit) (") r.11rrPnt t~v (b) Deferred tax Total tax expense I (credit) (VIII) IX Profit after tax (VII-VIII) X Other comprehensive income / (loss) Items that will not be reclassified to profit or loss (a) Re-measurement loss on defined benefits plans (b) Fair value gain/ (loss) from investment in equity instruments ( c) Income tax relating to items that will not be reclassified to profit or loss Items that will be reclassified to profit or loss (a) Exchange differences on translation of foreign operations (b) Exchange differences on net investment in foreign operations Total other comprehensive income/ (loss) (net of tax) XI Total comprehensive income, net of tax (IX+X) Profit attributable to: - Owners of the Company - Non-controlling interest Other comprehensive income / (loss) attributable to: - Owners of the Company - Non-controlling interest Total comprehensive income attributable to: - Owners of the Company - Non-controlling interest XII Equity share capital (face value of~ 2 each) (refer note 3) XIII Other equity XIV Earnings per equity share: (face value of? 2 each) (not annualised) (1) Basic in~ (refer note 8) (2) Diluted in ~ (refer note 8) See accompanying notes to the unaudited consolidated financial results 3 months ended 30-June-2026 Unaudited 9,463.60 83.10 9,546.70 4,023.40 653.60 (334.50) 1,626.50 125.10 617.70 1,696.40 14.40 8,422.60 1,124.10 1,124.10 330.00 (8.60) 331.20 792.90 (3.70) 0.10 0.90 (21.10) (39.60) (63.40) 729.50 658.70 134.20 (56.20) (7.20) 602.50 127.00 873.70 1.51 1.47 Preceding 3 months ended 31-March-2026 Audited {refer note 9} 9,199.60 159.20 9,358.80 3,639.20 920.10 (431.00) 1,498.20 145.20 604.10 1,689.00 41.60 8,106.40 1,252.40 1,252.40 202.00 295.70 588.60 663.80 (26.10) (0.30) 7.30 330.90 78.40 390.20 1,054.00 521.10 142.70 275.90 114.30 797.00 257.00 873.70 1.20 1.17 Corresponding 3 months ended in previous period 30-June-2025 Unaudited (Restated) {refer note 3} 7,916.40 68.40 7,984.80 3,124.80 523.20 157.20 1,387.90 204.30 555.90 1,572.70 (37.10) 7,488.90 495.90 (12.50) 483.40 2-40.10 (125.20) 114.90 368.50 0.10 224.30 120.60 345.00 713.50 318.10 50.40 296.10 48.90 614.20 99.30 500.70 0.74 0.73 (~in Million) Previous year ended 31-March-2026 Audited 34,203.10 435.50 34,638.60 13,769.30 2,505.90 (647.90) 5,655.00 692.10 2,336.40 6,378.50 17.00 30,706.30 3,932.30 (442.10) 3,490.20 G::J1.:i0 612.20 1,243.70 2,246.50 (30.90) (0.20) 7.80 897.70 194.60 1,069.00 3,315.50 1,772.80 473.70 790.30 278.70 2,563.10 752.40 873.70 28,236.90 4.09 4.01
Page 11
Viyash Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Regd. Office 3rd Floor Snvalli's Corporate Plot No. 290. Road No. 6. SYN 33 34P TO 39. GuNala Begum pet, Jubilee Hills Sha,kpet Hyde,abad-500033 . Telangana, India. E-mail · investorrelaticns@viyash .com E-mail · info@viyash .com, Website : www.viyash.com Tel No. +91 40 23635000 GIN- L99999TS1985PLC 196357 Note s: 1. The above statement of unaudited consolidated financial results of V1yash Sc1ent1fic Limited (the ~HoM1ng Company" or the "Company"), and its subs1dianes (the Holding Company and its subs1dianes together referred to as the "Group~) has been prepared 1n accordance with lhe Indian Accounling Standards ("Ind AS") prescribed under Section 133 of the Companies Act. 2013 ("the Act") read wi th relevant rules issued lhereunder. other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India rsEBI") . These results were reviewed and recommended by the Audit Commi ttee and approved by the Board of Directors at their meetrngs held on 11 August 2026. The Statutory Auditors have carried out a limited rev1ev-1 of the unaudited consotidated financia l results and issued unmodified reports thereon. 2. The Group 1s pnmanly engaged in the business of 'Pharmaceu!lca ls'. There rs no separate reportable segment as per Ind AS 108- Operating Segments. 3. The Board of Directors of the Company at their meetrng held on 26 September 2024 have approved the Composi te Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company). V1yash Life Sciences Pnvate L1m1ted, Symed Labs Limited. Vandana Life Sciences Pnvate L1m1ted, Appcure Labs Pnvate L1m1ted. Vindhya Pharma (India) Pnvale L1m1ted, SV Labs Private L1m1ted. Vindhya Organics Private Limited. Genin Life Sciences Private L1m1ted (referred to as 'transferor Companies') 1n terms of Section 230-232 and other aoolicable provisions of Companies Act. 2013 The Hon'ble National Company Law Tribunal (NCLT). Hyderabad v1de its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 Apnl 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. As per the terms of the Scheme. the Company has allotted 18.19.21 ,827 fully pa1d•up equity shares of face value oft 2 each. as per the share exchange ratio of 56 fully paid•up equity shares of face value oft 2 each of the Company for every 100 fully paid· up equity shares of face value of t 10 each held by eligible shareholder s of erstwhile Viyash Life Sciences Private Umited as on the record date. The Company has also allotted 2.03.41.257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warran t exchange ratio of 56 warrants of the Company for every 100 warrants held 1n erstwhile Viyash Life Sciences Private L1m1ted and received a consideration oft 925.20 million during the year ended 31 March 2026 (representing 25% on Warrant consideration as per the Scheme). The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103. 'Business Combinations of Entitles under Common Control', in accordance with the accounting treatment prescribed In the Scheme. Accordrnalv. the consolidated financial results of the Graue in resoect of the corresoondrna oner oeriods have been restated as ,f the aforesaid business combination had occurred from the beo1nnino of the oreced1no oenod <i.e. 01 Aonl 2024) as oer below: a Details of revenue and rant restated due to the Scheme of Amal amatron. Revenue from operattons Profit before tax Profit after lax Total comprehensive income, (net of tax) Basic earnings per equity share (in ') (not annualised) Diluted earnin s r uit share 1n t not annualised 4. Exce tional items include : Particul ars Expenses related to Scheme of Amalgamation Total Particul ars (a) The Group has recorded below transaction costs pertaining to Scheme t in Million Corresponding 3 months end ed in previous period 30-June-2025 Re orted 4.414.20 255.20 175.70 493.20 0.57 0.56 Note Reference (a) Restated 7,916.40 483.40 368.50 713.50 0.74 0.73 3 months ended 30-June-2026 Unaudited (i) Stamp duty recognized on an estima1ed basis amounting tot 296.50 million for the previous year ended 31 March 2026 payable pursuant to scheme. Preceding 3 months ended 31-March-2026 (refer note 9) Audited Corresponding 3 months ended in previous period 30-June-2025 ( refer note 3) Unaudited (Restated) 12.50 12.50 t in MU/ion Previous year ended 31-March-2026 Audited 442.10 442.10 (ii) Transactions costs with respect to fees payable to merchant banker in relation to Scheme amoun ting to~ 10.10 million for quarter ended 30 June 2025 and~ 107.60 million for the previous year ended 31 March 2026. (iii) O1her transaction costs with respect to fees payable to lawyers and other consultants engaged in relation to the Scheme amounting tot 2.40 million for quarter ended 30 June 2025 and t38 million for the year previous ended 31 March 2026. 5. Pursuant to the Composite Scheme of Amalgamation (refer note 3 above). the Board of Directors and Nomination and Remuneration Committee (NRC) at its meeting held on February 05, 2026 approved the adoption of Viyash Scientific Limited • Employee Stock Option Scheme 2026 {"ESOP Scheme 2026"). subJect to receipt of necessary statutory approvals. During the quarter ended 30 June 2026. on receipt of necessary approvals. Company has granted 13,098,000 employee stock options. representing 2.8% of the post-ama lgamation paid-up share capital of the Company under ESOP Scheme 2026. This has resulted in an incremental expense of - INR 193 million for the quarter ended 30 June 2026, which has been recognized under ~Employee benefit expense" in the financial results. 6. The Group has applied IND AS 29 Ac1.;ountlng for Hypennflat1onary economtes' on Turkish subs1dianes, since the Turkish Lira 1s a functiona l currency of these subs1dianes 1n Turkey which 1s a hypennflationary economy. In prepanng the consolidated financial results. the non-monetary assets (includes goodwill, property , plant and equipment . etc.). liabilities. owner's equity and statement of profit and loss of the aforesaid subsidiaries have been restated as on the reporting date by applying general price index of the Turkish economy. Considering that the presentation currency of consolidated financial results 1st. the restatement of comparative figures 1n consolidated financial results 1s not required. 7. The Group through its step.cjown wh~ ly owned subsidiary , Alivira Animal Health Limited . Ireland, has entered into a Sale and Purchase agreement rsPA~) on 21 July 2026 for acquisition of 100% of issued and outstanding share capital of BioForli fe Italia S.r.l. , Italy. subject to receipt of required approva ls for aggregate consideration of EURO 16.976 million {includrng deferred consideration of EURO 1.976 million linked to specified contractual•continuation conditions). There is no impact on the fi nancial results for the quarter ended 30 June 2026. 8. Weighted average number of shares considered for calculation of basic and diluted earnings per share for all the periods reported includes the weighted average effect of equity shares and warrants alloted pursuant to the Scheme as described in note 3 above and outstand ing share options under employees share option plan. 9. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures 1n respect of the full financial year and the published unaudited year to date figures upto the third quarter of the relevant financial year. Hyderabad, 11 August 2026 For Vivash Scientific Limited 11 i :~F;:•'k"•'• • Managing Director & Group CEO
Page 12
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 Annexure - B Disclosure under Regulation 30 read with Para A(1) of Part A of Schedule III of the SEBI Listing Regulations and the SEBI Circular No. HO/49/14/14(7)2025 -CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. No. Particulars Details i. Name of the entity, date & country of incorporation; Name: Alivira Vietnam Company Limited or such other name as may be approved by the relevant authorities. Date: To be incorporated Country of Incorporation: Vietnam ii. Name of holding company of the incorporated company and relation with the listed entity; The proposed entity, upon incorporation, will become a step -down sub sidiary of the Company , and wholly owned subsidiary of Alivira Animal Health Limited, India (“AAHL”) or Alivira animal Health Limited, Ireland (“AAHL Ireland”), as may be decided . C onsequently, upon incorporation, it shall become a related party in terms of applicable regulations. iii. Industry to which the entity being incorporated belongs; Pharmaceuticals iv. Brief background about t he entity incorporated in terms of products / line of business; Upon incorporation, the proposed entity is expected to undertake the importation, registration, marketing, sale and distribution of animal health products, active pharmaceutical ingredients (APIs), and phytogenic solutions in Vietnam. The entity is proposed to commercialize its products primarily through a distributor network, while also catering directly to select strategic key accounts. It is expected to provide commercial, technical and marketing support to customers and business partners to facilitate market development and business growth in Vietnam. v. Brief details of any governmental or regulatory approvals required for the incorporation; Local approvals as may be required from relevant regulatory agencies to complete the incorporation process. vi. Nature of consideration - whether cash consideration or share swap and details of the same; Cash consideration vii. Cost of subscription / price at which the shares are subscribed; Upon incorpora tion, i nvestment of upto USD 400,000 by AAHL or AAHL Ireland , as may be decided. viii. Percentage of shareholding / control by the listed entity and / or number of shares allotted. 100% investment will be held by AAHL or AAHL Ireland, as may be decided.
Page 13
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 Annexure C Disclosure under Regulation 30 read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. No. Particulars Remark a) Name of the Target en tity, details in brief such as size, turnover etc. Alivira Animal Health Limited , India (“ AAHL”) was incorporated in India on Sep tember 30, 2013, and is a wholly owned subsidiary of the Company. The turnover of AAHL for the financial year ended March 31, 2026, was Rs. 4494.53 Mn. b) Whether the acquisition of the Target entity falls within the related party Transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” AAHL, being wholly owned subsidiary of the Company, is a related party of the Company. While AAHL is a related party to the Company, the acquisition does not qualify as Related Party Transaction as per Regulation 2(zc) of the SEBI Listing Regulations. Except to the extent of shares held by the Company in AAHL India , none of the Company’s promoter/ promoter group / group companies have any interest in the said allotment. It is hereby clar ified that t he proposed conversion relates only to intercompany loans already extended in the past and does not involve any fresh infusion of capital funds by the Company. c) Industry to which Target entity being acquired belongs Pharmaceuticals d) Objects and impact of acquisition The proposed conversion is intended to strengthen AAHL’s capital structure and reduce interest burden. e) Brief details of any governmental or regulatory approvals required for the acquisition Not Applicable f) Indicative time period for completion of the acquisition The indicative time period for conversion of the loan into equity is by August 30, 2026. g) Consideration - whether cash consideration or share swap or any other form and details of the same; Conversion of intercompany loan to equity. h) Cost of acquisition and/or the price at Investment of upto Rs. 4,00,02,15,648
Page 14
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 which the shares are acquired i) Percentage of shareholding/ control acquired and/ or number of shares acquired The Company will continue to hold 100% shareholding in AAHL. j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); AAHL was incorporated in India on September 30, 2013, and is a wholly owned subsidiary of the Company. AAHL is in the business of veterinary products. Last 3 years turnover (Rs. In Million) FY 2023-24 – 3,784.20 FY 2024-25 – 3,681.42 FY 2025-26 – 4,494.53